 |
 |

HEALTH CARE REFORM
Going Off-label Without Venturing Off-CourseEvidence and Ethical Off-label Prescribing
Emily A. Largent, BS;
Franklin G. Miller, PhD;
Steven D. Pearson, MD, MS
Arch Intern Med. 2009;169(19):1745-1747.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Following US Food and Drug Administration (FDA) approval, clinicians may lawfully prescribe a drug or biologic agent for treatment regimens not specified in the approved labeling or package insert. This is known as off-label use. A recent study1 found that for 160 common drugs in the United States, off-label use accounted for 21% of all prescriptions. Many off-label uses are accepted as standard of care, for example, use of β-blockers for congestive heart failure. Many other off-label uses, however, lack evidence of clinical efficacy.1 In light of growing concerns about appropriateness and cost, off-label use has been identified as 1 aspect of problematic drug prescribing.2-3
Currently, there is little guidance to distinguish clearly between off-label uses that are well-supported by evidence and those that are not. In this article, we address that gap at the level . . . [Full Text of this Article] SIGNALS FOR SCRUTINY
New Drugs Novel Off-label Use Drugs With Known Serious Adverse Effects High-Cost Drugs EVIDENCE LEVELS TO GUIDE OFF-LABEL PRESCRIBING PHYSICIAN RESPONSIBILITIES AND ACTIONS Supported Off-label Use
Suppositional Off-label Use Investigational Off-label Use COMMENT
AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(19):1736.
FULL TEXT
|